Growth Hormone Deficiency Forecast in 9 Major Markets 2016-2026 - Analysis, Technologies & Forecasts Report - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Growth Hormone Deficiency Forecast in 9 Major Markets 2016-2026" report to their offering.

Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH), from the anterior pituitary gland. GHD can occur at any point during an individual's life, but is primarily defined as being of Childhood onset (CO) or Adult onset (AO). The majority of CO is congenital whereas AO forms tend to be acquired or idiopathic.

This report provides the current prevalent population for GHD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, India and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of GHD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Reason to Buy:

  • Able to quantify patient populations in global GHD's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of GHD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on GHD's prevalent population.
  • Identify sub-populations within GHD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of GHD patients.

Report Structure:

1 Introduction

2 Cause of the Disease

3 Risk Factors & Prevention

4 Diagnosis of the Disease

5 Variation by Geography/Ethnicity

6 Disease Prognosis & Clinical Course

7 Key Co-morbid Conditions/Features Associated with the Disease

8 Methodology for Quantification of Patient Numbers

9 Top-Line Prevalence for Growth Hormone Deficiency

10 Abbreviations used in the Report

11 Patient-Based Offering

12 Online Pricing Data and Platforms

13 References

14 Appendix

For more information visit http://www.researchandmarkets.com/research/jk6db5/growth_hormone

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals